Gender differences in vascular thromboses are well known, and there is evidence that platelets may be involved in these differences and that sex hormones affect platelet function. We characterized the expression of the estrogen receptor alpha (ER alpha), estrogen receptor beta (ER beta), progesterone receptor (PR), and androgen receptor (AR) in the megakaryocyte lineage. Megakaryocytes generated ex vivo from normal human CD34(+) stem cells contained RNA for ER beta and AR, which increased with cell differentiation. Platelets and human erythroleukemia (HEL) cells also contained ER beta and AR transcripts. No ER or or PR messenger RNA or protein was detected in the megakaryocyte lineage. Immunofluorescence microscopy showed that ER beta protein was present in glycoprotein (GP) IIb(+) megakaryocytes and the HEL megakaryocytic cell line in a predominantly cytoplasmic location. AR showed a cytoplasmic and nuclear distribution in GPIIb(+) and GPIIb(-) cells derived from CD34(+) cells and in HEL cells. Western immunoblotting confirmed the presence of ER beta and AR in platelets. Megakaryocyte and HEL AR expression was up-regulated by 1, 5, and 10 nmol/L testosterone, but down-regulated by 100 nmol/L testosterone, These findings indicate a regulated ability of megakaryocytes to respond to testosterone and suggest a potential mechanism through which sex hormones may mediate gender differences in platelet function and thrombotic diseases. (Blood, 2000;95:2289-2296) (C) 2000 by The American Society of Hematology.
机构:
Novartis Farmaceut SA, Clin Dev & Regulatory Affairs, Global Pharmacoepidemiol, Barcelona 08013, SpainNovartis Farmaceut SA, Clin Dev & Regulatory Affairs, Global Pharmacoepidemiol, Barcelona 08013, Spain
Castellsague, J
Gutthann, SP
论文数: 0引用数: 0
h-index: 0
机构:
Novartis Farmaceut SA, Clin Dev & Regulatory Affairs, Global Pharmacoepidemiol, Barcelona 08013, SpainNovartis Farmaceut SA, Clin Dev & Regulatory Affairs, Global Pharmacoepidemiol, Barcelona 08013, Spain
Gutthann, SP
Rodriguez, LAG
论文数: 0引用数: 0
h-index: 0
机构:
Novartis Farmaceut SA, Clin Dev & Regulatory Affairs, Global Pharmacoepidemiol, Barcelona 08013, SpainNovartis Farmaceut SA, Clin Dev & Regulatory Affairs, Global Pharmacoepidemiol, Barcelona 08013, Spain
机构:
Novartis Farmaceut SA, Clin Dev & Regulatory Affairs, Global Pharmacoepidemiol, Barcelona 08013, SpainNovartis Farmaceut SA, Clin Dev & Regulatory Affairs, Global Pharmacoepidemiol, Barcelona 08013, Spain
Castellsague, J
Gutthann, SP
论文数: 0引用数: 0
h-index: 0
机构:
Novartis Farmaceut SA, Clin Dev & Regulatory Affairs, Global Pharmacoepidemiol, Barcelona 08013, SpainNovartis Farmaceut SA, Clin Dev & Regulatory Affairs, Global Pharmacoepidemiol, Barcelona 08013, Spain
Gutthann, SP
Rodriguez, LAG
论文数: 0引用数: 0
h-index: 0
机构:
Novartis Farmaceut SA, Clin Dev & Regulatory Affairs, Global Pharmacoepidemiol, Barcelona 08013, SpainNovartis Farmaceut SA, Clin Dev & Regulatory Affairs, Global Pharmacoepidemiol, Barcelona 08013, Spain